Department of Health
and Human Services (HHS)
and Human Services (HHS)
September 7, 2021
RFA-NS-21-010 - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to inform applicants of a change to the Key Dates for Funding Opportunity Announcement (FOA) RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional). This FOA will be extended by two additional Council rounds. The following Due Dates have been added to this FOA: New Application Due Dates: October 14, 2022 and February 14, 2023; AIDS Application Due Dates: January 7, 2023 and May 7, 2023.
The following section of RFA-NS-21-010 has been modified:
Currently Reads:
Part 1. Overview Information
Key Dates:
| Application Due Date(s) |
November 18, 2020, March 24, 2021, July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022, by 5:00PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| AIDS Application Due Date(s) |
Standard dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| Scientific Merit Review | February 2021, June 2021, October 2021, February 2022, June 2022, October 2022 |
| Advisory Council Review | May 2021, October 2021, January 2022, May 2022, October 2022, January 2023 |
| Earliest Start Date | June 2021, November 2021, February 2022, April 2022, November 2022, February 2023 |
| Expiration Date | September 08, 2022 |
Modified to Read (changes shown in bold italics):
Part 1. Overview Information
Key Dates:
| Application Due Date(s) |
November 18, 2020, March 24, 2021, July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 14, 2023 by 5:00PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| AIDS Application Due Date(s) |
Standard dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| Scientific Merit Review | February 2021, June 2021, October 2021, February 2022, June 2022, October 2022, February 2023, June 2023 |
| Advisory Council Review | May 2021, October 2021, January 2022, May 2022, October 2022, January 2023, May 2023, October 2023 |
| Earliest Start Date | June 2021, November 2021, February 2022, April 2022, November 2022, February 2023, June 2023, November 2023 |
| Expiration Date | May 8, 2023 |
All other aspects of this FOA remain unchanged.
Charles Cywin, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: [email protected]